RNA activation

saRNA-mediated RNAa and the RITA Complex

The mechanism of saRNA-mediated RNAa centers around the RNA-induced transcriptional activation (RITA) complex. This complex includes:

• Argonaute 2 (AGO2): AGO2 binds to the guide strand of the saRNA and facilitates targeting to the gene promoter. AGO2 is the primary Argonaute protein involved in saRNA-mediated RNAa.
• RNA Helicase A (RHA): RHA is thought to unwind the DNA helix, allowing the saRNA to bind to its target sequence.
• CTR9 (Component of the PAF1 Complex): CTR9, a key part of the PAF1 complex (PAF1C), is recruited to the promoter. PAF1C plays a crucial role in regulating RNA Polymerase II (RNAP II) activity.

The RITA complex assembly at the target gene promoter leads to a shift in the transcriptional machinery, promoting the transition from paused to elongating RNAP II. This is evidenced by changes in phosphorylation patterns at the transcriptional start site (TSS): a decrease in Ser5-phosphorylated RNAP II (pausing) and an increase in Ser2-phosphorylated RNAP II (elongating). Histone H2B monoubiquitination is also an early epigenetic event associated with RNAa, promoting further histone modifications that enhance active transcription.

miRNA-mediated RNAa (mi-RNAa)

Endogenous miRNAs, typically known for their role in post-transcriptional gene silencing, can also activate gene expression. The mechanisms of mi-RNAa are diverse. Several models have been proposed:

• Release of Paused RNAP II: miR-34a, for example, has been shown to bind to a long non-coding RNA (lncRNA) transcribed from the ZMYND10 promoter. This interaction recruits the RNA-induced silencing complex (RISC), which then forms a complex with DDX21 and CDK9 (components of the positive transcription elongation factor b, P-TEFb). This complex facilitates the release of paused RNAP II at the promoter, allowing for active transcription.
• TATA Box Targeting: Some miRNAs including those encoded by HIV-1 virus and human endogenous ones have been shown to directly target the TATA box motif in gene promoters to facilitate pre-initiation complexes (PICs) assembly and transcription initiation.
• Targeting of RNA Transcripts: Some miRNAs can bind to RNA transcripts that overlap with the promoter.

• DNA Triplex Formation: miRNAs can directly bind double-stranded DNA (dsDNA) at purine-rich sequences, forming triple-helical structures that upregulate gene expression. This interaction, identified through biophysical methods and the computational algorithm Trident, suggests a novel mechanism of miRNA-mediated gene activation. Argonaute proteins may stabilize these miRNA-DNA triplexes.

Nuclear Import

A critical aspect of RNAa is the nuclear import of saRNAs and miRNAs. While the exact mechanisms are still under investigation, several pathways have been implicated:

• Importin-8: Importin-8 has been shown to mediate the nuclear import of mature miRNAs.
• AGO2-dependent transport: AGO2 itself may play a role in the nuclear localization of saRNAs.

As a Research Tool

RNAa has been used as a convenient tool by many scientists to study gene function in lieu of vector-based gene overexpression.

Therapeutic Applications

RNAa offers promising therapeutic potential because of its ability to increase gene expression. This provides a different approach for treating diseases caused by gene underexpression or loss-of-function mutations. saRNAs for a number of genes have been tested in various cell and animal disease models for therapeutic efficacy.

• Cancer: saRNAs have been used to reactivate tumor suppressor genes, inhibit cancer cell proliferation, and reduce tumor growth in animal models.
• Metabolic Disorders: saRNAs have been used to upregulate the expression of SIRT1, showing potential for reversing metabolic syndrome, and obesity.
• Cardiovascular Disorders: saRNAs targeting VEGFA gene in the form of shRNA have been tested for the treatment of peripheral artery disease and myocardial infarction. and erectile dysfunction (ED). saRNA-mediated activation of βII spectrin alleviated ischemia/reperfusion (I/R)-induced cardiac contractile dysfunction.
• Genetic and Neuromuscular Disorders: The application of RNAa has been investigated for Myotonic Dystrophy type 1 (DM1), a dominant inherited neuromuscular disorder. The core pathology of DM1 involves a toxic gain-of-function from expanded CUG repeats in the DMPK gene, which sequester Muscleblind-like (MBNL) proteins. This leads to a functional MBNL1 deficiency and a resulting disease-causing spliceopathy. In a study, saRNAs were designed to target the promoter of the MBNL1 gene. The saRNAs were shown to increase MBNL1 transcription and protein levels (approximately 1.5–3 fold) in various cell models, including those derived from DM1 patients. Critically, this upregulation of endogenous MBNL1 was sufficient to correct or significantly mitigate key molecular defects, such as the mis-splicing of the insulin receptor (INSR), a primary biomarker for DM1. The study provided a strong preclinical proof-of-concept for RNAa as a therapeutic strategy to address the root cause of DM1 and offered key engineering principles for future saRNA design.
• Neurodegenerative Disease: saRNAs targeting the BACE2 gene have been used to reduce Abeta production.
• Other Therapeutic Applications: saRNAs have been tested in several other disease models, including acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) and proliferative vitreoretinopathy (PVR).